Abstracts tagged "Lupus and mouse model"

Abstract Number: 1756 • 2015 ACR/ARHP Annual Meeting
The Oxidative Burst Mediates Anti-Inflammatory Clearance of Dead Cells in a Mouse Model of SLE and Inflammatory Arthritis
Jonas Hahn¹, Deborah Kienhöfer¹, Luis Munoz¹, Martin Herrmann², Gerhard Krönke³, Rikard Holmdahl⁴, Georg Schett⁵ and Markus Hoffmann¹, ¹Medicine III, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Medicine III, Rheumatology and Immunology, University of Erlangen-Nuremberg, Osterreich, Germany, ³Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: The production of reactive oxygen species (ROS) via the oxidative burst has recently been implicated in regulation of inflammation and protection from arthritis, multiple…
Abstract Number: 662 • 2014 ACR/ARHP Annual Meeting
Interferon Regulatory Factor-5 Promotes Disease in the MRL/Lpr Mouse Model of Lupus
Amanda Watkins¹, Ramon Bonegio², Guneet Kochar¹, Gabriella Wilson¹, Bari Laskow¹, Christophe Richez¹, Ian Rifkin¹ and Kei Yasuda³, ¹Boston University School of Medicine, Boston, MA, ²Renal, Boston University School of Medicine, Boston, MA, ³Medicine, Boston University School of Medicine, Boston, MA
Background/Purpose Interferon regulatory factor 5 (IRF5) polymorphisms are strongly associated with an increased risk of developing Systemic Lupus Erythematosus (SLE). SLE is caused, in part,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].